Cargando…

Phosphorylated Tau in Alzheimer’s Disease and Other Tauopathies

Alzheimer’s disease (AD) is the leading cause of dementia in elderly people. Amyloid beta (Aβ) deposits and neurofibrillary tangles are the major pathological features in an Alzheimer’s brain. These proteins are highly expressed in nerve cells and found in most tissues. Tau primarily provides stabil...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rawat, Priyanka, Sehar, Ujala, Bisht, Jasbir, Selman, Ashley, Culberson, John, Reddy, P. Hemachandra
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9654278/ https://www.ncbi.nlm.nih.gov/pubmed/36361631 http://dx.doi.org/10.3390/ijms232112841

Ejemplares similares

Therapeutics of Alzheimer’s Disease: Recent Developments
por: Burns, Scott, et al.
Publicado: (2022)

Support Provided by Caregivers for Community-Dwelling Diabetic Hispanic Adults with Intellectual Disabilities and Comorbid Conditions
por: Rawat, Priyanka, et al.
Publicado: (2023)

Caregivers with Cancer Patients: Focus on Hispanics
por: Bisht, Jasbir, et al.
Publicado: (2023)

Amyloid Beta in Aging and Alzheimer’s Disease
por: Sehar, Ujala, et al.
Publicado: (2022)

Comprehensive Understanding of Hispanic Caregivers: Focus on Innovative Methods and Validations
por: Sehar, Ujala, et al.
Publicado: (2023)

Alzheimer’s Disease and Alzheimer’s Disease-Related Dementias in African Americans: Focus on Caregivers
por: Kopel, Jonathan, et al.
Publicado: (2023)

Support Provided by Caregivers for Community-Dwelling Obesity Individuals: Focus on Elderly and Hispanics
por: Basu, Tanisha, et al.
Publicado: (2023)

Amyloid Beta and Phosphorylated Tau-Induced Defective Autophagy and Mitophagy in Alzheimer’s Disease
por: Reddy, P. Hemachandra, et al.
Publicado: (2019)

Tau Ser208 phosphorylation promotes aggregation and reveals neuropathologic diversity in Alzheimer’s disease and other tauopathies
por: Xia, Yuxing, et al.
Publicado: (2020)

Secernin-1 is a novel phosphorylated tau binding protein that accumulates in Alzheimer’s disease and not in other tauopathies
por: Pires, Geoffrey, et al.
Publicado: (2019)

“Don’t Phos Over Tau”: recent developments in clinical biomarkers and therapies targeting tau phosphorylation in Alzheimer’s disease and other tauopathies
por: Xia, Yuxing, et al.
Publicado: (2021)

Structure Based Design and Molecular Docking Studies for Phosphorylated Tau Inhibitors in Alzheimer’s Disease
por: Pradeepkiran, Jangampalli Adi, et al.
Publicado: (2019)

Tau Protein Interaction Partners and Their Roles in Alzheimer’s Disease and Other Tauopathies
por: Sinsky, Jakub, et al.
Publicado: (2021)

The Role of Obesity and Diabetes in Dementia
por: Selman, Ashley, et al.
Publicado: (2022)

The Link Between Tau and Insulin Signaling: Implications for Alzheimer’s Disease and Other Tauopathies
por: Gonçalves, Rafaella Araujo, et al.
Publicado: (2019)

Amyloid and Tau Positron Emission Tomography Imaging in Alzheimer’s Disease and Other Tauopathies
por: Maschio, Cinzia, et al.
Publicado: (2022)

PET Imaging of Tau Pathology in Alzheimer’s Disease and Tauopathies
por: James, Olga G., et al.
Publicado: (2015)

Tau-focused therapy and tau transmission: Implications for Alzheimer’s Disease and related tauopathies
por: Trojanowski, John Q
Publicado: (2013)

Tau Protein Hyperphosphorylation and Aggregation in Alzheimer’s Disease and Other Tauopathies, and Possible Neuroprotective Strategies
por: Šimić, Goran, et al.
Publicado: (2016)

Distribution of tau hyperphosphorylation in canine dementia resembles early Alzheimer’s disease and other tauopathies
por: Abey, Ajantha, et al.
Publicado: (2020)

Tau and neuroinflammation: What impact for Alzheimer's Disease and Tauopathies?
por: Laurent, Cyril, et al.
Publicado: (2018)

VPS35 regulates tau phosphorylation and neuropathology in tauopathy
por: Vagnozzi, Alana N., et al.
Publicado: (2021)

Extracellular truncated tau causes early presynaptic dysfunction associated with Alzheimer’s disease and other tauopathies
por: Florenzano, Fulvio, et al.
Publicado: (2017)

Cerebral Microvascular Accumulation of Tau Oligomers in Alzheimer’s Disease and Related Tauopathies
por: Castillo-Carranza, Diana L, et al.
Publicado: (2017)

Alzheimer risk gene product Pyk2 suppresses tau phosphorylation and phenotypic effects of tauopathy
por: Brody, A. Harrison, et al.
Publicado: (2022)

LRRK2 phosphorylates novel tau epitopes and promotes tauopathy
por: Bailey, Rachel M., et al.
Publicado: (2013)

Correction: Alzheimer risk gene product Pyk2 suppresses tau phosphorylation and phenotypic effects of tauopathy
por: Brody, A. Harrison, et al.
Publicado: (2022)

Ion Channel Formation by Tau Protein: Implications for Alzheimer’s Disease and Tauopathies
por: Patel, Nirav, et al.
Publicado: (2015)

Type-I Interferons in Alzheimer's Disease and Other Tauopathies
por: Sanford, Sophie A. I., et al.
Publicado: (2022)

Assessing THK523 selectivity for tau deposits in Alzheimer’s disease and non–Alzheimer’s disease tauopathies
por: Fodero-Tavoletti, Michelle T, et al.
Publicado: (2014)

Dynamics of Dynamin-Related Protein 1 in Alzheimer’s Disease and Other Neurodegenerative Diseases
por: Oliver, Darryll, et al.
Publicado: (2019)

Stabilization of Monomeric Tau Protein by All D-Enantiomeric Peptide Ligands as Therapeutic Strategy for Alzheimer’s Disease and Other Tauopathies
por: Altendorf, Tim, et al.
Publicado: (2023)

Transcellular Spreading of Tau in Tauopathies
por: Demaegd, Koen, et al.
Publicado: (2018)

Lysine-Directed Post-translational Modifications of Tau Protein in Alzheimer's Disease and Related Tauopathies
por: Kontaxi, Christiana, et al.
Publicado: (2017)

Transcriptional Signatures of Hippocampal Tau Pathology in Primary Age-Related Tauopathy and Alzheimer’s Disease
por: Stein-O’Brien, Genevieve L, et al.
Publicado: (2023)

Reduced VDAC1, Maintained Mitochondrial Dynamics and Enhanced Mitochondrial Biogenesis in a Transgenic Tau Mouse Model of Alzheimer’s Disease
por: Vijayan, Murali, et al.
Publicado: (2022)

Discovery and preclinical characterization of [(18)F]PI-2620, a next-generation tau PET tracer for the assessment of tau pathology in Alzheimer’s disease and other tauopathies
por: Kroth, Heiko, et al.
Publicado: (2019)

Molecular Mechanisms in the Pathogenesis of Alzheimer’s disease and Tauopathies-Prion-Like Seeded Aggregation and Phosphorylation
por: Hasegawa, Masato
Publicado: (2016)

Specific post-translational modifications of soluble tau protein distinguishes Alzheimer’s disease and primary tauopathies
por: Kyalu Ngoie Zola, Nathalie, et al.
Publicado: (2023)

Are Tau Aggregates Toxic or Protective in Tauopathies?
por: Cowan, Catherine M., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_nhsfcdnvnnbeq7ju7nonad1hib